LAEVOROC ONCOLOGY NEWS
ARTICLES &
PRESS RELEASES
28/02/2023 — Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
The Orphan Drug Designation underscores the significant unmet medical need and will grant LR 09 seven-year marketing exclusivity following drug approval by the FDA Zug, Switzerland, 28 February 2023: Laevoroc...
ARTICLES & PRESS RELEASES
28/02/2023 — Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
The Orphan Drug Designation underscores the significant unmet medical need and will grant LR 09 seven-year marketing exclusivity following drug approval by the FDA Zug, Switzerland, 28 February 2023: Laevoroc...
8/12/2022 — Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as a Novel Metabolic Immune Checkpoint
UCLA data in the Journal of Clinical Investigation supports LR09 drug development as a metabolic immune checkpoint inhibitor for the treatment of leukemia Zug, Switzerland, 8 December 2022: Laevoroc Oncology...
28/02/2023 — Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant
The Orphan Drug Designation underscores the significant unmet medical need…
8/12/2022 — Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as a Novel Metabolic Immune Checkpoint
UCLA data in the Journal of Clinical Investigation supports LR09…
EVENTS
EVENTS
UPCOMING EVENTS
PAST EVENTS
Bio€quity Europe – Milan
Laevoroc Oncology will be attending the 22nd BioEquity Europe hosted by Informa Connect Life Sciences in Milan 16–18 May 2022.
Swiss Biotech Day
Laevoroc Oncology will be attending Swiss Biotech Day, which is scheduled to take place on 2nd & 3rd May 2022.
Swiss Nordic Bio
Laevoroc Oncology will be attending Swiss Nordic Bio, which is scheduled to take place on 23 March 2022.
Digital RESI
Laevoroc Oncology will be attending Digital RESI which is scheduled to take place from 22 to 24 March 2022.